16.31
0.12%
-0.02
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
Revenues |
5.70%
40.52
|
42.97 | 41.47 | 44.30 | 37.92 |
Cost Of Revenue |
4.49%
15.89
|
16.64 | 16.52 | 15.33 | 15.08 |
Gross Profit |
6.46%
24.63
|
26.33 | 24.94 | 28.97 | 22.84 |
Operating Expenses
|
67.05%
29.69
|
90.11 | 32.62 | 32.60 | 35.40 |
Benefits Costs and Expenses |
57.62%
44.99
|
106.17 | 48.50 | 47.37 | 49.94 |
Costs And Expenses |
67.05%
29.69
|
90.11 | 32.62 | 32.60 | 35.40 |
Depreciation and Amortization |
6.51%
1.734
|
1.628 | 1.596 | 1.605 | 1.605 |
Operating Income/Loss |
92.06%
-5.063
|
-63.78 | -7.674 | -3.631 | -12.55 |
Income/Loss From Continuing Operations Before Tax |
92.93%
-4.471
|
-63.20 | -7.039 | -3.07 | -12.01 |
Income Tax Expense/Benefit, Deferred |
110.47%
0.193
|
-1.843 | -1.207 | -0.904 | -2.373 |
Income Tax Expense/Benefit |
121.08%
0.043
|
-0.204 | -0.463 | -0.329 | -1.664 |
Income/Loss From Continuing Operations After Tax |
92.83%
-4.514
|
-63.00 | -6.576 | -2.741 | -10.35 |
Net Income/Loss
|
92.83%
-4.514
|
-63.00 | -6.576 | -2.741 | -10.35 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
490.03K%
14.70
|
-0.003 | 14.63 | 14.69 | 14.65 |
Diluted Average Shares |
490.03K%
14.70
|
-0.003 | 14.63 | 14.69 | 14.65 |
Basic Earnings Per Share |
92.79%
-0.31
|
-4.30 | -0.45 | -0.19 | -0.71 |
Diluted Earnings Per Share |
92.79%
-0.31
|
-4.30 | -0.45 | -0.19 | -0.71 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):